SCHEMBL19355693

SCHEMBL19355693

CCc1cncc(OCC(F)(F)F)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 2/20 0.46
CHRNA4 P43681 2/20 0.46
ALDH1A1 P00352 2/20 0.42
MAPT P10636 2/20 0.42
CACNA1B Q00975 1/20 0.36
GGPS1 O95749 2/20 0.36
GRM2 Q14416 1/20 0.35
CYP17A1 P05093 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
KDM4E B2RXH2 1/20 0.34
USP2 O75604 1/20 0.34
HSP90AA1 P07900 1/20 0.34
HSP90AB1 P08238 1/20 0.34
THRB P10828 1/20 0.34
G6PD P11413 1/20 0.34
ALOX15 P16050 1/20 0.34
CASP1 P29466 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13735601 0.83 ALDH1A1 (0.46) CHRNB2ALDH1A1MAPTCACNA1BGRM2
Hydrochloric Acid SCHEMBL30939141 0.81 ALDH1A1 (0.44) CHRNB2ALDH1A1MAPTCACNA1BGRM2
SCHEMBL8184696 0.80 CHRNB2 (0.51) CHRNB2CHRNA4ALDH1A1GGPS1
SCHEMBL11918259 0.79 ALDH1A1 (0.44) CHRNB2CHRNA4ALDH1A1MAPTCACNA1B
SCHEMBL19446251 0.77 CHRNB2 (0.47) CHRNB2CHRNA4GGPS1
SCHEMBL19446198 0.76 CHRNB2 (0.46) CHRNB2CHRNA4GGPS1
SCHEMBL24534141 0.75 ALDH1A1 (0.63) ALDH1A1MAPTCACNA1BCYP17A1CYP2C9
SCHEMBL651977 0.75 ALDH1A1 (0.44) CHRNB2CHRNA4ALDH1A1MAPTMEN1
SCHEMBL10174185 0.75 CYP17A1 (0.43) ALDH1A1MAPTCYP17A1CYP2C9CYP2C19
SCHEMBL21268171 0.74 MAPT (0.43) ALDH1A1MAPTCYP17A1CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10183933-B2 Isoindolinone inhibitors of phosphatidylinositol 3-kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2019-01-22 US disclosed
EP-2516417-B1 ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE VERTEX PHARMA (US) 2017-10-11 EP disclosed
US-20170260175-A1 ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE VERTEX PHARMACEUTICALS INCORPORATED 2017-09-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170260175-A1 ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE PIK3CD, PIK3CA, PIK3R5 CHRNB2 4051/4885CHRNA4 4409/4885ALDH1A1 3381/4885
US-10183933-B2 Isoindolinone inhibitors of phosphatidylinositol 3-kinase PIK3CD, PIK3CA, PIK3R5 CHRNB2 4051/4885CHRNA4 4409/4885ALDH1A1 3381/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.